Objective:To study the predictive value of serum pregenomic RNA(pgRNA)on HBeAg clearance in patients with chronic hepatitis B with low HBeAg levels during pegylated interferon therapy.Methods:Twenty chronic hepatitis ...Objective:To study the predictive value of serum pregenomic RNA(pgRNA)on HBeAg clearance in patients with chronic hepatitis B with low HBeAg levels during pegylated interferon therapy.Methods:Twenty chronic hepatitis B patients with HBeAg positive and quantitative<50S/CO were selected for this study.The subjects underwent pegylated interferon therapy for 48-96 weeks and were followed up in the outpatient clinic after treatment.The patients were then divided into groups based on whether their HbeAg turned negative.The predictive ability of each indicator for HBeAg negative conversion was evaluated in the HBeAg negative group and the HBeAg positive group.Results:The results of logistic regression analysis suggested that pgRNA and HBcrAg were better indicators for predicting the clearance of HBeAg after treatment.Conclusion:For patients with chronic hepatitis B with low HBeAg levels,pgRNA is a good indicator in predicting HBeAg clearance during pegylated interferon therapy.展开更多
慢性乙型肝炎(Chronic hepatitis B,CHB)由乙型肝炎病毒(Hepatitis B Virus,HBV)感染所致,可发展至肝纤维化、肝硬化、肝癌,严重威胁患者健康,给患者和社会带来沉重的负担。HBV感染呈世界性流行,现代医学尚未有治愈的药物,在防治其并发...慢性乙型肝炎(Chronic hepatitis B,CHB)由乙型肝炎病毒(Hepatitis B Virus,HBV)感染所致,可发展至肝纤维化、肝硬化、肝癌,严重威胁患者健康,给患者和社会带来沉重的负担。HBV感染呈世界性流行,现代医学尚未有治愈的药物,在防治其并发症的发生,特别是抑制肝纤维化发生和进展方面的研究具有重要意义。近年来中医药被发现在治疗HBeAg阴性CHB方面有独特优势。文章整理总结了HBeAg阴性CHB的病因病机、中医辨证论治等方面的研究进展,以期为HBeAg阴性CHB的临床治疗提供借鉴和参考。展开更多
基金the grant from SPPH Incubator Fund for Development of Science and Technology(2021YJY-19)SPPH Foundation for Development of Science and Technology(2021BJ-26)International Science and Technology Cooperation Projects of Shaanxi Province(2022KW-14).
文摘Objective:To study the predictive value of serum pregenomic RNA(pgRNA)on HBeAg clearance in patients with chronic hepatitis B with low HBeAg levels during pegylated interferon therapy.Methods:Twenty chronic hepatitis B patients with HBeAg positive and quantitative<50S/CO were selected for this study.The subjects underwent pegylated interferon therapy for 48-96 weeks and were followed up in the outpatient clinic after treatment.The patients were then divided into groups based on whether their HbeAg turned negative.The predictive ability of each indicator for HBeAg negative conversion was evaluated in the HBeAg negative group and the HBeAg positive group.Results:The results of logistic regression analysis suggested that pgRNA and HBcrAg were better indicators for predicting the clearance of HBeAg after treatment.Conclusion:For patients with chronic hepatitis B with low HBeAg levels,pgRNA is a good indicator in predicting HBeAg clearance during pegylated interferon therapy.
文摘慢性乙型肝炎(Chronic hepatitis B,CHB)由乙型肝炎病毒(Hepatitis B Virus,HBV)感染所致,可发展至肝纤维化、肝硬化、肝癌,严重威胁患者健康,给患者和社会带来沉重的负担。HBV感染呈世界性流行,现代医学尚未有治愈的药物,在防治其并发症的发生,特别是抑制肝纤维化发生和进展方面的研究具有重要意义。近年来中医药被发现在治疗HBeAg阴性CHB方面有独特优势。文章整理总结了HBeAg阴性CHB的病因病机、中医辨证论治等方面的研究进展,以期为HBeAg阴性CHB的临床治疗提供借鉴和参考。